ATAI News and Press, ATAI Life Sciences N.V. From 01/09/24

2024-01-09 08:35:20 ET BT Brands  ( BTBD ) +135% . Sentage Holdings ( SNTG ) +95% . Juniper Networks  ( JNPR ) +23% jumps 25% on report HPE is nearing buyout deal. Syra Health  ( SYRA ) +17% . Elicio Therapeutics  ( ELT...

2024-01-04 15:05:54 ET More on ATAI Life Sciences Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value Atai Life Sciences climbs on Phase 1 data for ecstasy candidate Seeking Alpha’s Quant Rating on ATAI Life Scien...

Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidates Two patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intrave...

2024-01-02 15:43:22 ET More on ATAI Life Sciences Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value Seeking Alpha’s Quant Rating on ATAI Life Sciences Historical earnings data for ATAI Life Sciences Fina...

EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expected The PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD) measures, including subjective reports and blood-based biomarkers, showed dose-depende...

The use of psychedelics has grown significantly these past few years as more data on the substances’ health benefits is revealed in studies. Given that the drugs are still illegal in most parts of the country, it is important to find ways to consume them legally. Below, we look at lawful w...

The MAPS Public Benefit Corporation (MAPS PBC), a psychedelics-focused, drug-development company, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA). MAPS PBC is asking the FDA to approve the use of MDMA (ecstasy, molly) as a prescription medication for trea...

A new clinical study from the American Medical Association (AMA) has indicated that psilocybin-assisted psychotherapy may be safe and effective in the treatment of bipolar II disorder depressive episodes. The nonrandomized controlled study was conducted at Baltimore’s Sheppard Pratt Hosp...

Psychedelics have been subject to intense public and scientific scrutiny in recent years, thanks to claims of their medical efficacy. Countless studies have now found that psychedelics can induce profound mental changes in patients with hard-to-treat mental disorders such as post-traumatic stre...

2023-11-29 18:55:54 ET Summary ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various clinical trial phases, showing promising results. ...